1.Investigation and analysis of the current situation of radiation health management in private dental clinics in Laizhou City, China
Chinese Journal of Radiological Health 2025;34(2):254-258
		                        		
		                        			
		                        			Objective To investigate and analyze the current situation and existing issues in radiation health management in private dental clinics in Laizhou City, and put forward countermeasures and suggestions for standardizing radiation diagnosis and treatment behaviors and strengthening radiation health supervision and management. Methods The radiation protection management measures and supporting facilities of 41 private dental clinics were checked on site. Radiation health management data were collected. The qualified rates were determined according to the relevant national laws and regulations. Results All 41 (100%) clinics possessed Radiation Diagnosis and Treatment License, and 38 (92.7%) clinics had well-established radiation protection management systems. All 53 (100%) radiation workers held Radiation Worker Certificate, and 46 (86.8%) radiation workers had complete occupational health monitoring records. The qualified rates of quality control indicators and examination room protection indicators of 45 dental X-ray machines were 100%. The overall qualified rate of supporting facilities in the examination room was 86.7%. The qualified rates of examinee protection equipment and light box warning/door-lamp interlock were 88.9% and 95.6%, respectively. Conclusion The current situation of radiation health management in private dental clinics in Laizhou City is generally good, but there are still some shortcomings and deficiencies. It is necessary to strengthen the examination of the rational application of X-ray images in private dental clinics and the systematic learning and training of radiation protection knowledge. Further standardization of the oral radiation diagnosis and treatment behaviors is essential to ensure the health and safety of radiation workers, examinees, and the public.
		                        		
		                        		
		                        		
		                        	
2.Research on the Role and Clinical Application Value of the Histone H2A Deubiquitinase BAP1 in the Occurrence and Progression of Malignant Glioma Cells
Yufang LI ; Zhifeng LIN ; Ying XIANG ; Fei QI ; Feizhou HAN ; Zhongli QIAN ; Tao WANG ; Xu CHEN
Journal of Modern Laboratory Medicine 2024;39(2):7-11,33
		                        		
		                        			
		                        			Objective To explore the role of breast/ovarian cancer susceptibility gene 1 associated protein 1(BAP1)in the occurrence and progression of human malignant glioma and the feasibility of BAP1 as a clinical diagnostic marker for malignant glioma.Methods The differential expression of BAP1 in normal and glioma tissue was analyzed based on the GSE4290 and GSE90598 sub-datasets from the gene expression omnibus(GEO)database.Receiver operating characteristic(ROC)curve analysis was conducted to assess the early diagnostic value of BAP1 for malignant glioma.Primary lesion tissues from 28 nonpaired malignant glioma patients and non-tumor brain tissues removed by internal decompression surgery in 5 patients with traumatic brain injury collected independently were collected,and the expression levels of BAP1 were measured using quantitative real-time polymerase chain reaction(qRT-PCR).Specific small interfering RNAs(siRNAs)targeting BAP1 were transiently transfected into U251 cells to further evaluate their interference efficiency.Flow cytometry was employed to analyze changes in the cell cycle and apoptosis of U251 cells with BAP1 knockdown.Results The results of bioinformatics showed that the expression of BAP1 in malignant glioma tissues was lower than that in normal brain tissues(GSE 4290:1 209±18.49 vs 1 476±53.90,GSE 90598:5.19±0.10 vs 5.65±0.21),and the differences were significant(t=5.115,2.267,all P<0.05).ROC curve showed that BAP1 could efficiently differentiate malignant glioma tissue from normal brain tissue(GSE4290:AUC=0.78,GSE90598:AUC=0.75,all P<0.05).The expression level of BAP1 in primary malignant glioma tissue was lower than that in normal brain tissue(0.27±0.04 vs 1.06±0.07),and the difference was significant(t=10.22,P<0.001).After down-regulating the expression of BAP1 in U251 cells,the proportion of S phase cells increased from 17.59%to 27.21%(siBAP1-1)and 25.79%(siBAP1-2),respectively,and the differences were significant(t=6.576,6.642,all P<0.01).However,the apoptosis levels decreased from 10.17%to 2.70%(siBAP-1)and 3.00%(siBAP-2),respectively,and the differences were significant(t=10.31,9.428,all P<0.01).Conclusion Histone H2A deubiquitinase BAP1 could exert the function of tumor suppressor genes by inhibiting rapid cell cycle progression and promoting apoptosis in malignant glioma,and could serve as a potential clinical diagnostic biomarker for malignant glioma.
		                        		
		                        		
		                        		
		                        	
3.Comparative study of BFH-OST and OSTA in predicting the risk of osteoporosis in postmenopausal women
China Modern Doctor 2024;62(27):43-45,51
		                        		
		                        			
		                        			Objective To compare the predictive effect on the risk of osteoporosis in postmenopausal women with the new Beijing Friendship Hospital osteoporosis self-assessment tool(BFH-OST)and osteoporosis self-assessment tool for Asians(OSTA).Methods A total of 115 postmenopausal women who met the criteria in Civil Aviation General Hospital from January 2021 to November 2022 were randomly enrolled,and dual energy X-ray absorptiometry(DXA)was used as the diagnostic criterion.Analyzing the diagnostic efficacy of BFH-OST and OSTA through receiver operating characteristic(ROC)curve analysis.Results BFH-OST and OSTA were significantly correlated with DXA in the diagnosis of osteoporosis(P<0.01),the area under the curve(AUC)of BFH-OST was 0.819,the cut-off value was ≤12.2,the sensitivity was 81.25%,and the specificity was 75.90%.The AUC of OSTA was 0.809,the cut-off value was ≤-1.2,the sensitivity was 81.25%,and the specificity was 72.29%.There was a significant difference between the ROC curves of BFH-OST and OSTA(P<0.05).Conclusion BFH-OST and OSTA have predictive effects on the risk of osteoporosis in postmenopausal women.BFH-OST is better than OSTA in predicting and diagnosing osteoporosis in postmenopausal women.
		                        		
		                        		
		                        		
		                        	
4.Wnt/β-catenin Signaling Cascades in Cardiovascular Diseases
Yan-Fei QI ; Yan-Ping LIU ; Wen-Qing XU ; Xiao-Xue YAN
Progress in Biochemistry and Biophysics 2024;51(10):2328-2339
		                        		
		                        			
		                        			Cardiovascular diseases are a group of disorders of the heart and blood vessels, primarily including coronary heart disease, stroke, and other diseases. It is the world’s leading cause of death, and its incidence is increasing yearly. Hypertension is a major risk factor for cardiovascular disease. Wnt signaling comprises a series of highly conservative cascading events controlling fundamental biological processes. Wnt signaling pathways include the canonical Wnt pathway (or Wnt/β-catenin pathway), the non-canonical planar cell-polarity pathway, and the non-canonical calcium-dependent pathways. Abnormal Wnt signaling promotes cell proliferation and differentiation, cardiac malformations, various malignancies, so drugs targeting Wnt signaling play a great therapeutic potential. Wnt/β‑catenin pathway is involved in the occurrence and development of cardiovascular diseases such as atherosclerosis and stroke by regulating cell proliferation, migration, apoptosis, blood-brain barrier permeability, inflammation, oxidative stress, and immune response. Based on the latest research progress, this review summarizes the role of Wnt/β‑catenin signaling in cardiovascular diseases, in order to provide new ideas for the prevention and treatment of cardiovascular diseases. 
		                        		
		                        		
		                        		
		                        	
5.Research progress on carrier-free and carrier-supported supramolecular nanosystems of traditional Chinese medicine anti-tumor star molecules
Zi-ye ZANG ; Yao-zhi ZHANG ; Yi-hang ZHAO ; Xin-ru TAN ; Ji-chang WEI ; An-qi XU ; Hong-fei DUAN ; Hong-yan ZHANG ; Peng-long WANG ; Xue-mei HUANG ; Hai-min LEI
Acta Pharmaceutica Sinica 2024;59(4):908-917
		                        		
		                        			
		                        			 Anti-tumor traditional Chinese medicine has a long history of clinic application, in which the star molecules have always been the hotspot of modern drug research, but they are limited by the solubility, stability, targeting, bioactivity or toxicity of the monomer components of traditional Chinese medicine anti-tumor star molecules and other pharmacokinetic problems, which hinders the traditional Chinese medicine anti-tumor star molecules for further clinical translation and application. Currently, the nanosystems prepared by supramolecular technologies such as molecular self-assembly and nanomaterial encapsulation have broader application prospects in improving the anti-tumor effect of active components of traditional Chinese medicine, which has attracted extensive attention from scholars at home and abroad. In this paper, we systematically review the research progress in preparation of supramolecular nano-systems from anti-tumor star molecule of traditional Chinese medicine, and summarize the two major categories and ten small classes of carrier-free and carrier-based supramolecular nanosystems and their research cases, and the future development direction is put forward. The purpose of this paper is to provide reference for the research and clinical transformation of using supramolecular technology to improve the clinical application of anti-tumor star molecule of traditional Chinese medicine. 
		                        		
		                        		
		                        		
		                        	
6.Ovarian-adnexal reporting and data system ultrasound 2022 version(O-RADS US v2022)and it combined with risk of malignancy index 4 for differential diagnosis of benign and malignant adnexal tumors
Jian LI ; Fangxin LIU ; Jianguo QI ; Tinglan XU ; Yongfeng REN ; Zhou WANG ; Fei CHEN ; Zizhuo LI
Chinese Journal of Medical Imaging Technology 2024;40(6):893-897
		                        		
		                        			
		                        			Objective To observe the value of ovarian-adnexal reporting and data system ultrasound 2022 version(O-RADS US v2022)and it combined with risk of malignancy index 4(RMI4)for differential diagnosis of benign and malignant adnexal tumors.Methods Data of 126 patients with adnexal tumors confirmed by surgical pathology were retrospectively analyzed.O-RADS US v2022 was used to classify:1-3 as benign lesion and 4-5 as malignant lesion.RMI4 classification took 450 as the critical value.And classification was performed based on the two combination.Taking pathological results as gold standard,receiver operating characteristic(ROC)curve was drawn to evaluate the efficacy of O-RADS US v2022 and RMI4 alone or combination for the differential diagnosis of benign and malignant adnexal tumors.Results Among 126 cases,94 were benign and 32 were malignant tumors.The sensitivity,specificity,accuracy and area under the curve(AUC)of O-RADS US v2022 were 78.13%,80.85%,80.16%and 0.795,respectively.The diagnostic results of RMI4 were 71.88%,84.04%,80.95%and 0.780,respectively.The specificity and accuracy of the combination of the two(93.62%,92.06%)were higher than those of O-RADS US v2022(x2=7.322,5.967,P=0.007,0.015)or RMI4(x2=4.625,5.331,P=0.032,0.021),while no significant difference in sensitivity and AUC(87.50%,0.906)was found with O-RADS US v2022 or RMI4(all P>0.05).Conclusion O-RADS US v2022 could effectively differentiate benign and malignant adnexal tumors,and combined with RMI4 could improve the diagnostic specificity and accuracy.
		                        		
		                        		
		                        		
		                        	
7.Chinese expert consensus on blood support mode and blood transfusion strategies for emergency treatment of severe trauma patients (version 2024)
Yao LU ; Yang LI ; Leiying ZHANG ; Hao TANG ; Huidan JING ; Yaoli WANG ; Xiangzhi JIA ; Li BA ; Maohong BIAN ; Dan CAI ; Hui CAI ; Xiaohong CAI ; Zhanshan ZHA ; Bingyu CHEN ; Daqing CHEN ; Feng CHEN ; Guoan CHEN ; Haiming CHEN ; Jing CHEN ; Min CHEN ; Qing CHEN ; Shu CHEN ; Xi CHEN ; Jinfeng CHENG ; Xiaoling CHU ; Hongwang CUI ; Xin CUI ; Zhen DA ; Ying DAI ; Surong DENG ; Weiqun DONG ; Weimin FAN ; Ke FENG ; Danhui FU ; Yongshui FU ; Qi FU ; Xuemei FU ; Jia GAN ; Xinyu GAN ; Wei GAO ; Huaizheng GONG ; Rong GUI ; Geng GUO ; Ning HAN ; Yiwen HAO ; Wubing HE ; Qiang HONG ; Ruiqin HOU ; Wei HOU ; Jie HU ; Peiyang HU ; Xi HU ; Xiaoyu HU ; Guangbin HUANG ; Jie HUANG ; Xiangyan HUANG ; Yuanshuai HUANG ; Shouyong HUN ; Xuebing JIANG ; Ping JIN ; Dong LAI ; Aiping LE ; Hongmei LI ; Bijuan LI ; Cuiying LI ; Daihong LI ; Haihong LI ; He LI ; Hui LI ; Jianping LI ; Ning LI ; Xiying LI ; Xiangmin LI ; Xiaofei LI ; Xiaojuan LI ; Zhiqiang LI ; Zhongjun LI ; Zunyan LI ; Huaqin LIANG ; Xiaohua LIANG ; Dongfa LIAO ; Qun LIAO ; Yan LIAO ; Jiajin LIN ; Chunxia LIU ; Fenghua LIU ; Peixian LIU ; Tiemei LIU ; Xiaoxin LIU ; Zhiwei LIU ; Zhongdi LIU ; Hua LU ; Jianfeng LUAN ; Jianjun LUO ; Qun LUO ; Dingfeng LYU ; Qi LYU ; Xianping LYU ; Aijun MA ; Liqiang MA ; Shuxuan MA ; Xainjun MA ; Xiaogang MA ; Xiaoli MA ; Guoqing MAO ; Shijie MU ; Shaolin NIE ; Shujuan OUYANG ; Xilin OUYANG ; Chunqiu PAN ; Jian PAN ; Xiaohua PAN ; Lei PENG ; Tao PENG ; Baohua QIAN ; Shu QIAO ; Li QIN ; Ying REN ; Zhaoqi REN ; Ruiming RONG ; Changshan SU ; Mingwei SUN ; Wenwu SUN ; Zhenwei SUN ; Haiping TANG ; Xiaofeng TANG ; Changjiu TANG ; Cuihua TAO ; Zhibin TIAN ; Juan WANG ; Baoyan WANG ; Chunyan WANG ; Gefei WANG ; Haiyan WANG ; Hongjie WANG ; Peng WANG ; Pengli WANG ; Qiushi WANG ; Xiaoning WANG ; Xinhua WANG ; Xuefeng WANG ; Yong WANG ; Yongjun WANG ; Yuanjie WANG ; Zhihua WANG ; Shaojun WEI ; Yaming WEI ; Jianbo WEN ; Jun WEN ; Jiang WU ; Jufeng WU ; Aijun XIA ; Fei XIA ; Rong XIA ; Jue XIE ; Yanchao XING ; Yan XIONG ; Feng XU ; Yongzhu XU ; Yongan XU ; Yonghe YAN ; Beizhan YAN ; Jiang YANG ; Jiangcun YANG ; Jun YANG ; Xinwen YANG ; Yongyi YANG ; Chunyan YAO ; Mingliang YE ; Changlin YIN ; Ming YIN ; Wen YIN ; Lianling YU ; Shuhong YU ; Zebo YU ; Yigang YU ; Anyong YU ; Hong YUAN ; Yi YUAN ; Chan ZHANG ; Jinjun ZHANG ; Jun ZHANG ; Kai ZHANG ; Leibing ZHANG ; Quan ZHANG ; Rongjiang ZHANG ; Sanming ZHANG ; Shengji ZHANG ; Shuo ZHANG ; Wei ZHANG ; Weidong ZHANG ; Xi ZHANG ; Xingwen ZHANG ; Guixi ZHANG ; Xiaojun ZHANG ; Guoqing ZHAO ; Jianpeng ZHAO ; Shuming ZHAO ; Beibei ZHENG ; Shangen ZHENG ; Huayou ZHOU ; Jicheng ZHOU ; Lihong ZHOU ; Mou ZHOU ; Xiaoyu ZHOU ; Xuelian ZHOU ; Yuan ZHOU ; Zheng ZHOU ; Zuhuang ZHOU ; Haiyan ZHU ; Peiyuan ZHU ; Changju ZHU ; Lili ZHU ; Zhengguo WANG ; Jianxin JIANG ; Deqing WANG ; Jiongcai LAN ; Quanli WANG ; Yang YU ; Lianyang ZHANG ; Aiqing WEN
Chinese Journal of Trauma 2024;40(10):865-881
		                        		
		                        			
		                        			Patients with severe trauma require an extremely timely treatment and transfusion plays an irreplaceable role in the emergency treatment of such patients. An increasing number of evidence-based medicinal evidences and clinical practices suggest that patients with severe traumatic bleeding benefit from early transfusion of low-titer group O whole blood or hemostatic resuscitation with red blood cells, plasma and platelet of a balanced ratio. However, the current domestic mode of blood supply cannot fully meet the requirements of timely and effective blood transfusion for emergency treatment of patients with severe trauma in clinical practice. In order to solve the key problems in blood supply and blood transfusion strategies for emergency treatment of severe trauma, Branch of Clinical Transfusion Medicine of Chinese Medical Association, Group for Trauma Emergency Care and Multiple Injuries of Trauma Branch of Chinese Medical Association, Young Scholar Group of Disaster Medicine Branch of Chinese Medical Association organized domestic experts of blood transfusion medicine and trauma treatment to jointly formulate Chinese expert consensus on blood support mode and blood transfusion strategies for emergency treatment of severe trauma patients ( version 2024). Based on the evidence-based medical evidence and Delphi method of expert consultation and voting, 10 recommendations were put forward from two aspects of blood support mode and transfusion strategies, aiming to provide a reference for transfusion resuscitation in the emergency treatment of severe trauma and further improve the success rate of treatment of patients with severe trauma.
		                        		
		                        		
		                        		
		                        	
8.Progress in enteral nutrition implementation in critically ill patients receiving vasoactive medications
Hong-Yu ZHANG ; Li-Bing JIANG ; Hai-Long WANG ; Yong-An XU ; Cheng-Fei WANG ; Feng RUAN ; Wen-Qi QI ; Su-Min ZUO ; Shan-Xiang XU
Parenteral & Enteral Nutrition 2024;31(3):176-183
		                        		
		                        			
		                        			Nutritional therapy is a core component of critically ill patient management,and the enteral route has become the preferred method due to its dual roles of nutrition and non-nutrition. The use of vasoactive medications makes enteral nutrition decisions more challenging for these patients. This review systematically examines the pathophysiological effects of vasoactive medications on gastrointestinal tract of critically ill patients,the current value and safety of enteral nutrition in this patient's population,summarizes the optimal strategies for implementing enteral nutrition in these patients for clinical reference.
		                        		
		                        		
		                        		
		                        	
9.Effects and mechanism of safflower yellow on non-Hodgkin's lymphoma
Yan-Fei YI ; Mei-Jin XU ; Qi WANG
The Chinese Journal of Clinical Pharmacology 2024;40(6):839-843
		                        		
		                        			
		                        			Objective To study the influences of safflower yellow on the proliferation,apoptosis and cell cycle of non-Hodgkin's lymphoma(NHL)by regulating Wnt/β-catenin signaling pathway.Methods Raji cells were cultured in vitro and randomly divided into control group(conventional culture),safflower yellow group(30 μg·mL-1 safflower yellow),lithium chloride group(20 mmol·L-1 LiCl)and safflower yellow+LiCl group(30 μg·mL-1 safflower yellow+20 mmol·L-1 LicL).Cell proliferation,apoptosis,cell cycle distribution,apoptosis and cell cycle related protein expression were detected in each group.Nude mice were subcutaneously inoculated with Raji cells in the right anterior armpit to construct the NHL transplanted tumor model,and they were randomly grouped into Nu-control group,Nu-safflower yellow(7.5 mg·kg-1 safflower yellow)group,Nu-LiCl(1 mg·kg-1 safflower yellow)group,Nu-safflower yellow(7.5 mg·kg-1 safflower yellow)+LiCl(1 mg·kg-1 safflower yellow)group.After grouping and treating with safflower yellow and LiCl,the tumor weight and volume of nude mice in each group were measured.Results The Wnt1 protein levels of control group,safflower yellow group,LiCl group and safflower yellow+LiCl group were 0.64±0.11,0.19±0.04,1.07±0.40 and 0.59±0.07,respectively;the apoptosis rates were(5.13±0.67)%,(57.68±7.31)%,(0.91±0.29)%,(7.24±1.40)%,respectively;the protein levels of B-cell lymphoma-2(Bcl-2)were 0.53±0.09,0.09±0.02,0.99±0.14,0.49±0.07;the protein levels of P21 were 0.56±0.12,1.08±0.20,0.13±0.04,0.59±0.11,respectively.Compared with the control group,there were statistically significant differences of the above indexes between the safflower yellow group and LiCl group,the safflower yellow+LiCl group and the safflower yellow pigment group(all P<0.05).The tumor volume of Nu-control group,Nu-safflower yellow group,Nu-LiCl group and Nu-safflower yellow+LiCl group was(915.34±61.43),(578.46±42.54),(1 310.84±93.16),(878.75±56.20)mm3,respectively;the tumor weight was(0.86±0.13),(0.45±0.09),(1.31±0.15),(0.75±0.17)g,respectively.Compared with the Nu-control group,there were statistically significant differences of the obove indexes between the Nu-safflower yellow group and Nu-LiCl group,the Nu-safflower yellow+LiCl group and the Nu-safflower yellow pigment group(all P<0.05).Conclusion Safflower yellow can down regulate the expression of Wnt/β-catenin pathway protein,thereby inducing the cell cycle arrest of NHL cells,inhibiting their proliferation and tumor growth in nude mice,and promoting their apoptosis.
		                        		
		                        		
		                        		
		                        	
10.Research status of anti-inflammatory effect of traditional Chinese medicine based on NLRP3 inflammatory body
Fu-Mei XU ; Jun-Yuan ZENG ; Lei ZHAO ; Qi-Li ZHANG ; Peng-Fei XIA ; Yin-Qiang JIA ; Jie WANG ; Peng-Xia FANG ; Yan-Li XU
The Chinese Journal of Clinical Pharmacology 2024;40(6):923-927
		                        		
		                        			
		                        			Inflammasome is a kind of intracellular polyprotein complex,which is an important component of the complex system of local inflammatory microenvironment after human tissue damage.When the inflammasome is activated,it induces the activation of cysteine aspartate proteinase 1(caspase-1),mediates the maturation and secretion of proinflammatory cytokines,such as interleukin(IL)-1 β and IL-18,and induces cell death,which plays an important role in regulating the host immune response to pathogen infection and tissue repair of cell damage.Nod-like receptor protein 3(NLRP3)inflammatory body,which is composed of NLRP3,pro-cysteine aspartic acid specific protease-1(pro-caspase-1)and apoptosis-related spot-like protein(ASC),is the most deeply and widely studied type of inflammatory body,which plays an important role in the regulation of inflammation.When NLRP3 inflammatory bodies are activated,inflammatory mediators are produced and released,which participate in the occurrence and development of a variety of inflammatory diseases.Some studies have shown that traditional Chinese medicine can improve the pathological state of a variety of diseases by inhibiting NLRP3 inflammatory bodies,and play a role in the prevention and treatment of a variety of inflammatory diseases,including cardiovascular diseases,joint inflammation,diabetes and so on.This paper systematically combs the mechanism of NLRP3 inflammatory bodies,and summarizes the latest research reports on the effects of traditional Chinese medicine compound prescription,traditional Chinese medicine monomers and traditional Chinese medicine extracts on NLRP3 inflammatory bodies in the treatment of inflammatory diseases,in order to provide new ideas for the further study of the pathogenesis and drug treatment of many inflammatory diseases.
		                        		
		                        		
		                        		
		                        	
            
Result Analysis
Print
Save
E-mail